Literature DB >> 31753195

Utilizing UVA-1 Phototherapy.

Smriti Prasad1, Jennifer Coias1, Henry W Chen1, Heidi Jacobe2.   

Abstract

There is a long history of utilization of phototherapy for treatment of skin conditions. Because of its longer wavelength, UVA1 phototherapy is able to penetrate into the dermis and subcutis. This depth of penetration, combined with its unique immunomodulating properties, makes UVA1 an effective treatment modality for many immune-mediated skin diseases. In some cases, it performs better than other types of phototherapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lichen sclerosus; Morphea; Phototherapy; Systemic sclerosis; UVA phototherapy; UVA-1 phototherapy

Mesh:

Year:  2020        PMID: 31753195     DOI: 10.1016/j.det.2019.08.011

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Primary Localized Cutaneous Amyloidosis: A Retrospective Study of an Uncommon Skin Disease in the Largest Tertiary Care Center in Switzerland.

Authors:  Carole Guillet; Simona Steinmann; Julia-Tatjana Maul; Isabel Kolm
Journal:  Dermatology       Date:  2021-09-15       Impact factor: 5.197

Review 2.  UVA-Triggered Drug Release and Photo-Protection of Skin.

Authors:  Vega Widya Karisma; Wei Wu; Mingxing Lei; Huawen Liu; Muhammad Farrukh Nisar; Matthew D Lloyd; Charareh Pourzand; Julia Li Zhong
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 3.  Morphea: progress to date and the road ahead.

Authors:  Laila Abbas; Adrienne Joseph; Elaine Kunzler; Heidi T Jacobe
Journal:  Ann Transl Med       Date:  2021-03

Review 4.  The Damaging Effects of Long UVA (UVA1) Rays: A Major Challenge to Preserve Skin Health and Integrity.

Authors:  Françoise Bernerd; Thierry Passeron; Isabelle Castiel; Claire Marionnet
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

5.  Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.

Authors:  Anna Malewska-Woźniak; Agnieszka Osmola-Mañkowska; Zygmunt Adamski
Journal:  Postepy Dermatol Alergol       Date:  2021-08-24       Impact factor: 1.664

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.